The Tugaske Project.
Source: International Mining.
  • Gensource Potash Corporation (GSP) has closed a non-brokered private placement of units and flow-through common shares
  • Under the first tranche, the company issued 2,400,000 FT shares for gross proceeds of $480,000.00
  • Under the second tranche, the company issued 11,969,998 units for gross proceeds of $1,795,499.70
  • Net proceeds from the sale of the units will be used to advance the Tugaske Project
  • Gensource is a fertilizer development company based in Saskatoon
  • Gensource Potash Corp. (GSP) opened trading at C$0.135

Gensource Potash Corporation (GSP) has closed its previously announced non-brokered private placement of units and flow-through common shares.

Under the first tranche of the offering, which closed on December 31, 2022, the company issued 2,400,000 FT shares for gross proceeds of $480,000.00.

Under the second tranche, the company issued 11,969,998 units for gross proceeds of $1,795,499.70. Each unit consists of one common share and one common share purchase warrant. Each warrant is exercisable for one additional common share for a period of 24 months.

Commissions totalling $27,300 and 157,000 non-transferable warrants were paid to eligible finders.

Proceeds will be used to advance the Tugaske Project and for general working capital purposes.

All securities issued are subject to a statutory hold period expiring May 27, 2023.

Gensource is a fertilizer development company based in Saskatoon and is on track to become the next fertilizer production company in that province.

Gensource Potash Corporation (GSP) opened trading at C$0.135.

More From The Market Online

Tilray Brands launches health-conscious cannabis drinks

Tilray Brands (TSX:TLRY) showcases two new cannabis-infused beverages from XMG to court more health-conscious consumers.

Now trading on the TSX Venture Exchange: Kootenay Resources Inc.

Shares in Kootenay Resources Inc. (TSXV:KTRI) began trading on the TSX Venture Exchange as a Tier 2...

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.